Sharemaestro Newsreel

SIGA Q2 2026 Earnings: Lower TPOXX Sales Compress Revenue and Margins

SIGA Technologies reported a significant decline in Q2 2026 revenue and EPS due to lower TPOXX product sales and an unfavorable product mix, which compressed margins. The company delivered TPOXX to both U.S. and international customers, but the completion of a key U.S. procurement …

Xeris Biopharma Holdings, Inc. reports results for the quarter ended June 30 - Earnings Summary

Xeris Biopharma Holdings, Inc. has released its earnings summary for the quarter that concluded on June 30. The report is provided by Refinitiv and is available to TradingView users with unlimited access to news articles.

Xeris Pharmaceuticals’ Earnings Call Highlights Growth Momentum

Earnings call transcript: Organogenesis Q2 2026 miss sends shares lower

Viatris Inc (VTRS) (Q2 2026) Earnings Call Highlights: Strong Growth and Raised Guidance Amid ...

Viatris Inc (VTRS) reported strong Q2 2026 results with $3.8 billion in revenues, a 3.5% operational growth year-over-year, and raised its full-year guidance. Key drivers included robust performance in Greater China and advancements in its R&D pipeline. The company also highlighted challenges such as …

Enterprise value to EBIT forward of Talphera, Inc. – DUS:R5XA

This page from TradingView provides financial data for Talphera, Inc. (R5XA) on the Dusseldorf Stock Exchange, specifically focusing on its enterprise value to EBIT forward metric. The content emphasizes the financial overview of the company, indicating that no trades were made and the market …

Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Top Estimates

Organogenesis (Nasdaq: ORGO) sets up $75M at-the-market stock sale

Organogenesis Holdings Inc. has established an at-the-market sales agreement with BTIG, LLC and Citizens JMP Securities, LLC to offer and sell up to $75 million of its Class A common stock. Sales will occur from time to time through the agents on the Nasdaq …

BioAge Labs, Inc. Stock 12‑Month Price Target Cut to $35.62, Implies 224% Upside

BioAge Labs, Inc. (BIOA) has seen its average 12-month price target cut to $35.62 from $39.88, according to 8 analysts, yet this still implies a significant 224% potential upside based on its closing price. Despite the target reduction, the consensus rating from 9 analysts …

Biofrontera Inc (BFRI) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Biofrontera Inc (BFRI), detailing its current earnings forecast score, average price target from analysts, and expected revenue and EPS for upcoming quarters. Two analysts rate BFRI as a "Buy" with a price target of $6.00, suggesting a …

Evolus Inc. Earnings Call Signals Confident Growth

Evolus, Inc. reported strong Q2 earnings with double-digit revenue growth and a third consecutive quarter of positive adjusted EBITDA, driven by its toxin franchise and growing international presence. Despite increased operating expenses and tariff uncertainty, the company raised its 2026 revenue guidance and reaffirmed …

Cronos Group Inc (CRON) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic ...

Cronos Group Inc (CRON) reported record net revenue, gross profit, and adjusted EBITDA in Q2 2026, with consolidated net revenue up 58% year-over-year to $53 million, driven by strong performance from its Spinach brand in Canada and international expansion. Despite facing regulatory uncertainties in …

Earnings call transcript: Cronos Group posts Q2 2026 beat, shares jump 13.2%

Cronos Group reported a strong Q2 2026, beating Wall Street estimates with record revenue and profit, which caused its shares to jump by 13.2%. The cannabis company saw significant growth in Canada, Israel, and other international markets, driven by higher selling prices, an improved …

Prestige Consumer Healthcare Inc. 2026: Revenue $265.71M, EPS $0.61— 10-Q Summary

Prestige Consumer Healthcare Inc. reported a Q2 2026 revenue increase to $265.71M, up 6.5% year-over-year, driven by growth in both North America and International markets. Despite revenue growth, net income and diluted EPS declined by 38.5% and 35.8% respectively compared to the prior-year quarter. …

Viatris Inc. Stock 12‑Month Price Target Raised to $18.71, Implies 6% Upside

Viatris Inc. (VTRS) has seen its average 12-month price target raised from $18.14 to $18.71 by 7 analysts, suggesting a 6% potential upside from its August 5th closing price. The consensus analyst rating remains a "Buy," with 5 out of 12 analysts recommending a …

Why Cronos Group (TSX:CRON) Is Up 6.4% After Swinging To US$32 Million Quarterly Profit

Viatris Inc (VTRS) Shares Fall 7.6% -- GF Value Says Still Overvalued

Viatris Inc (VTRS) shares fell 7.6% to $16.29, which is still 47.7% above its GF Value of $11.03, indicating the stock is significantly overvalued. The company has a GF Score of 58/100, with weak growth potential, and recent insider selling further suggests a cautious …

Form 8K Caring Brands Inc For: 6 August By Investing.com

Investing.com reported that Caring Brands Inc. filed a Form 8K on August 6th. The article is a brief announcement about this financial filing, indicating it was published by Investing.com UK.

SIGA Technologies (NASDAQ: SIGA) Q2 income drops to $12.5M

SIGA Technologies reported a significant drop in Q2 2026 revenue to $41.0 million, down from $81.1 million a year prior, primarily due to decreased U.S. government purchases of oral TPOXX. Net income consequently fell to $12.5 million from $35.5 million. Despite the revenue decline, …

SIGA: Q2 2026 delivered $38M in revenues, $12M net income, and expanded global TPOXX reach

SIGA Technologies Inc. reported $38 million in product revenues for Q2 2026, primarily from U.S. and international TPOXX deliveries, alongside a net income of $12 million and robust cash reserves. The company is advancing new U.S. contracts and international expansion efforts, despite encountering slower …

SIGA Technologies (SIGA) Stock Rises on Q2 2026 Earnings

Sonoma Pharmaceuticals reports 60% revenue growth in Q1

Sonoma Pharmaceuticals (NASDAQ:SNOA) announced a 60% increase in revenue to $6.4 million for its first fiscal quarter ending June 30, 2026, compared to the previous year. The company also significantly reduced its net loss per share by 88% to $0.09 and achieved positive EBITDA …

Emergent BioSolutions Announces Restructuring Amid Turnaround Efforts

SIGA Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

United Therapeutics Corp (UTHR) CEO sells 9,500 shares under 10b5-1 plan

United Therapeutics Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options at $135.42 per share and subsequently sold 9,500 shares in multiple transactions on August 5, 2026. These actions were conducted under a pre-arranged 10b5-1 trading plan established on …

Amphastar Pharmaceuticals (NASDAQ:AMPH) Posts Better-Than-Expected Sales In Q2 CY2026

Amphastar Pharmaceuticals (NASDAQ:AMPH) reported better-than-expected Q2 CY2026 results, with revenue of $183.9 million exceeding analyst estimates by 2% and non-GAAP profit of $0.91 per share significantly beating consensus estimates. The company achieved 5.4% year-on-year revenue growth and highlighted successful key goals including overall revenue …

Amphastar Pharmaceuticals (NASDAQ: AMPH) Q2 revenue rises 5% with margin gains

Amphastar Pharmaceuticals reported a 5% increase in Q2 2026 net revenues to $183.9 million, driven by growth in new products like Ipratropium bromide, despite declines in others such as BAQSIMI and Glucagon. The company achieved a gross margin expansion to 50.8%, although GAAP net …

Elanco raises 2026 outlook after strong second-quarter results

Elanco Animal Health Inc. reported a 10% increase in second-quarter revenue to $1.37 billion, leading the company to raise its full-year financial guidance for the second time. The growth was attributed to strong performance of new products like Zenrelia and Credelio Quattro, as well …

Viatris Inc. stock falls Thursday, underperforms market

Viatris Inc. (VTRS) stock fell 7.71% to $16.29 on Thursday, marking its second consecutive day of losses. This decline occurred during a broader market downturn, with the S&P 500 Index and Dow Jones Industrial Average also experiencing losses.

Caring Brands Provides Intellectual Property Portfolio Update

Caring Brands Inc. announced an update on its intellectual property portfolio, which now includes five issued U.S. patents. These patents cover two key product platforms

ANI Pharmaceuticals earnings on deck as rare disease shift accelerates By Investing.com

ANI Pharmaceuticals is set to report Q2 earnings, with investors focusing on the company's shift towards rare disease treatments, particularly Cortrophin Gel. Analysts predict $2.05 EPS on $260.85 million revenue, and the market will scrutinize Cortrophin's sustained momentum, profitability amidst rising royalties and operating …

FMR LLC discloses 15% ownership of Phibro Animal Health (PAHC) Class A shares

FMR LLC and Abigail P. Johnson have reported a 15.0% beneficial ownership stake in Phibro Animal Health Corp's Class A common stock, totaling 3,160,280.92 shares as of June 30, 2026. FMR LLC holds sole voting power over 3,159,853 shares and sole dispositive power over …

Bausch Health Companies Inc. (BHC.TO) Stock Price, News, Quote & History

This page provides comprehensive financial data for Bausch Health Companies Inc. (BHC.TO), including its current stock price, historical performance, key financial statistics, and analyst ratings. The company, which operates as a diversified specialty pharmaceutical and medical device firm, saw its stock close at 8.28 …

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026

Amphastar Pharmaceuticals, Inc. reported net revenues of $183.9 million for the second quarter of 2026, marking a 5% increase year-over-year. GAAP net income was $30.3 million ($0.67 per share), while adjusted non-GAAP net income reached $40.8 million ($0.91 per share). The company highlighted continued …

Arrowstreet Capital Limited Partnership Buys Shares of 102,643 Dr. Reddy's Laboratories Ltd $RDY

Arrowstreet Capital Limited Partnership recently acquired 102,643 shares of Dr. Reddy's Laboratories (NYSE:RDY), valued at approximately $1.42 million. This move comes as other institutional investors also increased their holdings in the company. Despite these purchases, Dr. Reddy's stock has faced downward pressure, with shares …

Amylyx Pharmaceuticals Narrows Q2 2026 Loss to -$0.39/Share

Amylyx Pharmaceuticals reported a wider-than-expected net loss of $0.39 per share for Q2 2026, missing the Street's estimate of $0.37, yet this represented a 15.2% improvement from the prior year. Despite the miss, the stock remained flat, and analysts maintain a bullish outlook with …